Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Interesting retrospective analysis (n=613) presented by Davide Massa, finding that patients with TNBC and pCR after neoadjuvant treatment harbor a relevant risk of recurrence if the disease was N+ and low-TILs. Caveat: only 20% pts with prior IO.”
More updates on ESMO Breast 2025 on OncoDaily.